Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Avoidance of undesirable replication intermediates in plasmid propagation

a technology of undesirable replication intermediates and plasmids, applied in the direction of dna/rna vaccination, biocide, antibody medical ingredients, etc., can solve the problems of reducing and reducing the yield of desired products. , to achieve the effect of increasing the distance between the origin of replication

Inactive Publication Date: 2006-11-30
MANNKIND CORP
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008] In one aspect of the invention the production of the side-products is eliminated by inverting the orientation of the origin of replication relative to the eukaryotic element(s). In another aspect of the invention production of the side-products is eliminated by increasing the distance between the origin of replication and the eukaryotic element(s). In yet another aspect of the invention an immunostimulatory sequence is inserted between the origin of replication and the eukaryotic element(s) so that the side products may be used as a vaccine adjuvant.

Problems solved by technology

When the plasmid is used in pharmaceutical products, as in gene therapy or DNA vaccination procedures, these side-products complicate production and the acquisition of regulatory approval.
The diversion of replicative machinery and chemical precursors constitutes a drain on bacterial metabolism potentially reducing yield of the desired product.
Moreover, the side products require characterization and very possibly removal by an additional purification step.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Avoidance of undesirable replication intermediates in plasmid propagation
  • Avoidance of undesirable replication intermediates in plasmid propagation
  • Avoidance of undesirable replication intermediates in plasmid propagation

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0034] The plasmid pCTL002, a pVAX1 derivative, was propagated using in two different bacterial host strains, DH5α (sold by Life Technologies, Rockville, Md.) and DH10B (also known as Top10 as sold by Invitrogen Corporation, Carlsbad, Calif.) in 1.5 liter cultures using LB+kanamycin at 37° C. for 16 hrs. at 250 rpm in a rotary shaking incubator. Approximately two-thirds less replication intermediate accumulated in DH10B compared to DH5α (see FIG. 1A). Using the above conditions and DH10B the effect of temperature was examined by comparing cultures grown at 33, 35, and 37° C. and it was found that the ratio of plasmid to replication intermediate could be improved approximately 2.5-fold (see FIG. 1B). Twelve, sixteen, and twenty hour cultures were also compared, indicating that longer cultures resulted in less accumulation of replication intermediate relative to plasmid (FIG. 1B). In other experiments no effect of speed of shaking was noted.

example 2

[0035] Two deletions were prepared in pCTL007 beginning at the NdeI site located midway through the CMV enhancer and continuing to either 1) the AflII site 5′ of start codon; or 2) an AflII* site ˜100 bases into the IRES (see FIG. 2A). Deletion 1) eliminated the ˜600 bp intermediate as well as an ˜360 bp intermediate (see FIG. 2B, clone 1), A ˜300 bp intermediate was unaffected. Deletion 2) eliminated all of the replication intermediates (see FIG. 2B, clone 10).

[0036] More concentrated material and gels providing greater resolution reveal a total of five replication intermediates in pCTL007 preparations (see FIG. 2C): The ˜300 bp band above is actually a doublet of 280 and 310 bp bands. Additionally there is a faint band at 490 bp. The ˜600 bp band can also be seen to be closer to 575 bp. All of these sizes are based on relative mobility of the bands versus commercial size standards in agarose gel electrophoresis and assessed by eye, and are thus still approximate. The cloning proc...

example 3

[0037] The 411 bp NdeI-NheI fragment of pCTL007, corresponding to most of the CMV promoter, but excluding the 18- and 16-base pair repeats at −427 to −410 and −413 to −398 of the CMV sequence, was replaced with an RSV promoter plus variable amounts of the removed CMV sequences. One construct, effectively deleting −209 onward of the CMV sequence and thus the termination site giving rise to the 580 bp fragment, nonetheless still gives rise to a fragment of similar size (see FIG. 3, clone 3). The termination site for this fragment is within the RSV promoter sequences, in the general vicinity of the transcriptional start site. Binding sites for several transcription factors are present although similarity to the transcription factor binding sites represented by the CMV repeat sequences is not readily discerned.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Digital informationaaaaaaaaaa
Digital informationaaaaaaaaaa
Distanceaaaaaaaaaa
Login to View More

Abstract

Disclosed herein are improved plasmid shuttle vectors, vaccines based on them, and methods related to their construction and use. Particular arrangements of functional elements of such plasmids, namely origins of replication and eukaryotic transcription / translation control elements, which give rise to generally undesirable side-products upon propagation of the plasmids in bacterial culture are disclosed. These side-products apparently arise as terminated replication intermediates. Strategies both to eliminate accumulation of these side-products, and to make them useful as a vaccine adjuvant, are described.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] The present application is a divisional of and claims priority to U.S. patent application Ser. No. 10 / 437,830, filed May 13, 2003, which is a divisional of and claims priority to U.S. patent application Ser. No. 09 / 715,835, filed Nov. 16, 2000, now U.S. Pat. No. 6,7098,44, issued on Mar. 23, 2004. The disclosure of the prior applications is hereby expressly incorporated by reference in its entirety.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The invention disclosed herein relates to methods and compositions for the efficient production of bacterial plasmid-based shuttle vectors free of linear plasmid-derived DNA contaminants, and particularly such vectors as might be used in DNA vaccination and gene therapy. [0004] 2. Description of the Related Art [0005] The application of recombinant DNA technology to eukaryotic cells has come to rely on shuttle vectors, plasmids that can be readily produced in bacterial cultur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00C12N15/86C12N15/74C12N15/85
CPCA61K39/39A61K48/0091A61K2039/53C12N2840/203C12N15/74C12N15/85A61K2039/55561
Inventor LEVY, JOHN
Owner MANNKIND CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com